



epinephrine in management 
of patients with cardiac 
arrest: a meta-analysis
ABSTRACT
Objective. A combination of vasopressin and epinephrine may be more effective than epinephrine alone in cardiopulmonary 
resuscitation (CPR), but evidence is lacking to make clinical recommendations. This meta-analysis compares the efficacy 
of vasopressin and epinephrine used together versus epinephrine alone in cardiac arrest (CA).
Methods. We searched MEDLINE and EMBASE for randomized trials comparing the efficacy of vasopressin and epineph-
rine versus epinephrine alone in adults with cardiac arrest. The primary outcome was the return of spontaneous circulation 
(ROSC) and the survival rate on admission and discharge .We also analyzed ROSC in subgroups of patients presenting with 
different arrest rhythms, such as asystole, pulseless electrical activity (PEA), ventricular fibrillation (VF).
Results. We analyzed 6 randomized trials out of 485 articles. We did not find evidence supporting the superiority of vasopres-
sin and epinephrine used in combination, except for the survival rate at 24h 2.99 95% CI(1.43,6.28). No evidence supports 
the conclusion that vasopressin combined with epinephrine is better than epinephrine alone for ROSC, even amongst 
subgroups of patients.
Conclusion. This systematic review of the efficacy of vasopressin and epinephrine use found that its combined use is better 
for 24h survival rate but only in one study which included 122 patients. Further investigation will be needed to support the 
use of this combination for cardiac arrest management.
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Introduction
Survival rates for cardiac arrest pati-
ents, both in and out of hospital, are 
poor. Furthermore, survival without 
severe neurological impairment has 
not improved over the past few deca-
des. Epinephrine has been used during 
cardiopulmonary resuscitation for more 
than 100 years, (1-3) but has become 
controversial because it is associated 
with increased adverse effects. 
An increasing body of evidence from 
laboratory investigations suggests that 
vasopressin may represent a promising 
alternative vasopressor for use during 
cardiac arrest and resuscitation. Seve-
ral clinical trials have demonstrated 
superior survival rates with the use of 
vasopressin instead of epinephrine. 
(4,5) Recently, the potential benefit of 
the administration of both drugs has 
drawn researchers’ attention. There 
have been several human studies in 
which some patients received both 
vasopressin and epinephrine. Among 
those trials, some have reported more 
desirable outcomes with the admini-
stration of both drugs, including increa-
sed ROSC and survival rate. (6-8)
The current international guidelines for 
CPR recommend the use of vasopre-
ssin during cardiac resuscitation as 
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a secondary alternative. This recom-
mendation could lead to the use of 
vasopressin for millions of cardiac arre-
sts worldwide. However, some clinical 
studies yielded contrasting findings. 
Therefore, our aim was to investigate 
the effectiveness of vasopressin and 
epinephrine for the treatment of pati-
ents with cardiac arrest.
Materials and methods 
We searched MEDLINE, from January 
1966 to December 2008, and EMBASE, 
from January 1950 to December 2008, 
for research papers.
Keywords used in this search were 
(cardiac arrest) or (cardiopulmonary 
resuscitation) or (cardiopulmonary-
cerebral resuscitation) and epineph-
rine or adrenaline and vasopressin or 
argipressin or (antidiuretic hormone). 
In MEDLINE, the search was limited 
by the search words “Publication Date 
since 1966/01/01 till 2008/12/31”, 
“English” and “Human”. We excluded 
those research papers with the fol-
lowing keywords: “case reports”, “ 
letter”, “review”, “practice guideline”, 
“review literature”, “review of reported 
cases”, “review, academic”, “review, 
multicase”, “review, tutorial”, “scientific 
integrity review”, “congresses”, “inter-
view”, “overall”, “comment”, “news”, 
“newspaper article” and “address”. In 
EMBASE, the search was limited by the 
search words: “Publication Date since 
„1950 till 2008”, “English” and “Human”. 
The search strategy was reviewed by 
library personnel to ensure that it was 
complete. We did not limit the articles 
published as abstracts only. The ref-
erences of articles were searched for 
citations which may have been missed 
by the electronic search.
Eligible patients had a cardiac arrest 
and had been treated with CPR. The 
diagnosis of cardiac arrest and CPR 
was based on International guidelines. 
The process of diagnosis and mana-
gement was registered according to 
the Utstein model. We looked at ran-
domized trials comparing vasopressin 
to epinephrine for adults with cardiac 
arrest. Patients in the treatment gro-
ups were those who suffered a cardiac 
arrest and who had received vasopre-
ssin and epinephrine during CPR. The 
sequences of drug administration were 
not restricted. Patients in the control 
groups were those who experienced a 
cardiac arrest and were treated by CPR 
with epinephrine alone. Efficacy was 
compared between the treatment and 
control groups. The incidence of the 
ROSC, survival rate at 24h, survival to 
hospital admission, survival to hospi-
tal discharge and neurologic outcome 
were recorded. 
Odds ratio (OR) and 95% confidence 
intervals (95% CI) were calculated for 
the articles included. Pooled estima-
tes of the odds ratio and 95% CI were 
obtained by the fixed-effects model of 
Peto with Review Manager 5.0 software. 
When there was heterogeneity, OR and 
95%CI were obtained by the random-
effect model of Mantel-Haenszel with 
Review Manager 5.0 software. Publica-
tion bias was assessed by Funnel plot.
Results
The search retrieved 485 papers, and 8 
of them were cohort studies on cardio-
pulmonary resuscitation, vasopressin 
and epinephrine. Among the 8 articles, 
one was limited to 10 patients and was 
published in abstract form only. The 
reports do not provide detailed informa-
tion of treatment protocols or its study 
populations. One of the 8 papers just 
describes the comparisons of vaso-
pressin and epinephrine for CPR. Two 
articles were finally excluded from this 
meta-analysis. Only six cohort studies 
were included in this meta-analysis to 
be analyzed for the effect of the asso-
ciation of vasopressin and epinephrine 
in CPR. Participants and the selected 
study design characteristics of the six 
cohort studies included in the meta-
analysis are detailed in table 1. (7-12)
Finally, the study by Stiell et al. was an 
in-hospital study in which time to initial 
drug administration was rapid (1.6min 
to CPR, 2.8 min to Advanced Cardio-
vascular Life Support (ACLS)), but the 
other five studies were out-of-hospital 
studies. The methodologies for the six 
studies were deemed too different to 
be compared and thus a meta-anal-
ysis was not attempted to combine 
in-hospital and out-of-hospital arrests 
together.
Comparing the outcome of 
vasopressin and epinep-
hrine versus epinephrine 
alone for CPR
1. We compared the rate of ROSC 
between the vasopressin and epinep-
hrine and epinephrine alone groups. 
The rate of ROSC was compared 
between two groups in five articles. 
Among the five articles, none conclu-
ded that the combination group did 
increase the rate of ROSC (1.05, 95%CI 
0.92, 1.19). This meta-analysis indi-
cates that compared with epinephrine 
alone, the combination group did not 
improve outcome (figure 1). 
2. We compared the survival rate 
between the two groups. First, the 24 
h survival rate was compared between 
the two groups. Two articles included 
and one concluded that patients rece-
iving vasopressin or epinephrine had 
an improved 24 h survival rate. Second, 
three articles compared the survival 
rate on admission. Two concluded 
significant differences between the two 
groups, while the others had contrary 
results. The last survival rate we com-
pared was the survival on discharge. 
Five articles did this comparison, with 
only one finding significant differences. 
However, a meta-analysis indicates that 
the combination of vasopressin and 
epinephrine only significantly impro-
ved the 24 h survival rate (2.99, 95%CI 
1.43, 6.28) (figure 2.1-2.3).
3. We compared the rate of ROSC 
according to the subgroups of patients 
with cardiac arrest, selected according 
to the Utstein Consensus Conferen-
ce. Subgroup analyses were made 
between the vasopressin and epinep-
hrine group and epinephrine alone 
group. Although one out of three inclu-
ded studies revealed that the combina-
tion group increased the rate of ROSC 
among patients with asystole and one 
of five studies indicated a significant 
difference in patients with ventricular 
fibrillation (VF), our meta-analysis did 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Return of spontaneous circulation.
Study or Subgroup
C.W. Callaway  2006






Heterogeneity: Chi² = 8.46, df = 4 (P = 0.08); I² = 53%











































vas and epi epi Peto Odds Ratio Peto Odds Ratio
Peto, Fixed, 95% CI
0.01 0.1 1 10 100
Favours epi only Favours vaso and epi
Figure 2.1. Survival rate at 24h.
Study or Subgroup




Heterogeneity: Chi² = 1.06, df = 1 (P = 0.30); I² = 6%

























vaso and epi epi alone Peto Odds Ratio Peto Odds Ratio
Peto, Fixed, 95% CI
0.01 0.1 1 10 100
Favours epi only Favours vaso and epi
Figure 2.2. Survival rate on admission.
Study or Subgroup





Heterogeneity: Tau² = 0.21; Chi² = 12.68, df = 2 (P = 0.002); I² = 84%































vaso and epi epi alone Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours epi only Favours vaso and epi
Study or Subgroup






Heterogeneity: Tau² = 0.41; Chi² = 12.56, df = 3 (P = 0.006); I² = 76%





































vaso and epi epi alone Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours epi only Favours vaso and epi
Figure 2.3. Survival rate at discharge.
95%CI 0.92, 1.28 and (0.91, 95%CI 
0.61, 1.35)). When pulseless electri-
cal activity (PEA) was the initial rhythm, 
ROSC did not differ between groups in 
our meta-analysis (1.32, 95%CI 0.98, 
1.79) (figure 3.1-3.3).
Potential Publication Bias
Potential publication bias (for the pri-
mary endpoint) was based on visual 
analysis of the funnel plot. The distribu-
tion is roughly symmetrical; thus, there 
is no strong evidence of publication 
bias (figure 4). 
Discussion
For patients in cardiac arrest, admi-
nistration of epinephrine appears to 
increase myocardial oxygen demand 
and consumption, decreases myocar-
dial adenosine triphosphate (ATP) with 
pro-arrhythmic effects, and increases 
myocardial lactate levels. (13-17) It may 
cause severe tachycardia immedia-
tely after ROSC, (18,19) and the most 
serious side effect of epinephrine is 
the increase in myocardial oxygen 
consumption during VF and myocar-
dial dysfunction in the post-resuscita-
tion phase. (20) The recently published 
European Resuscitation Council CPR 
Guidelines state that 'current eviden-
ce is insufficient to support or refute 
the routine use of any particular drug 
or sequence of drugs'; the respective 
CPR algorithm primarily recommends 
injection of 1 mg epinephrine every 3–5 
minutes, while vasopressin may also be 
injected. (21) In contrast, the approach 
of the American Heart Association CPR 
guidelines is more liberal, stating that 
'one dose of vasopressin may replace 
either the first or second dose of epi-
nephrine'. (22)
Vasopressin has been shown to incre-
ase coronary perfusion pressure and 
brain perfusion more effectively than 
epinephrine. (4,23) Since it was found 
that endogenous vasopressin levels 
in successfully resuscitated patients 
were significantly higher than levels in 
patients who died, (2) it was postulated 
that it might be beneficial to administer 
vasopressin during CPR. Other proper-
ties unique to vasopressin may also 
contribute to its synergistic effects with 
epinephrine. The V2 receptor vasodila-
tory activity of vasopressin may mitigate 
end organ hypoperfusion that results 
from multiple doses of epinephrine. 
(21) Combining both drugs may com-
bine both beneficial effects and avoid 
complications of injecting excessive 
dosages of one drug alone. In a series 
of animal studies, the group of subjects 
that received vasopressin and epinep-
hrine appeared to have a more rapid 
rise in coronary perfusion pressure, 
(24) higher levels of left ventricular myo-
cardial blood flow during CPR, (25) 
higher resuscitation rates, and impro-
ved cerebral blood flow (25,26,27) than 
the group that received epinephrine 
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only, perhaps because of a synergistic 
effect of epinephrine and vasopressin. 
(28-30) 
Two previous meta-analyses have inve-
stigated whether vasopressin is superi-
or to epinephrine in the management 
of cardiac arrest. The first, which inclu-
ded 2 human studies and 33 animal 
studies published before 2003, found 
vasopressin equivalent to epinephrine 
in humans, but significantly superior 
to epinephrine in animals. (31) In a 
second meta-analysis, which included 
5 human studies, the investigators con-
cluded that there is no clear advantage 
of vasopressin over epinephrine in the 
treatment of cardiac arrest in regard to 
failure of ROSC, hospital admission, 
hospital discharge and survival rates at 
24 hours. And in the secondary anal-
ysis, subgroup analysis based on ini-
tial cardiac rhythm showed no statisti-
cally significant difference. (5) Another 
meta-analysis of the combination of 
vasopressin and epinephrine versus 
repeated doses of epinephrine alone 
,which included 3 studies, found trends 
towards better ROSC but equivocal 
effects on survival. (32)
Our results, which include not only 
ROSC, hospital admission, hospital 
discharge and survival rates in the first 
24 hours, but also subgroups based 
on initial cardiac rhythm, provide the 
best available estimates of efficiency 
between the addition of vasopressin 
to epinephrine and epinephrine alone. 
Despite the sensitivity of the search 
strategy used and the large number of 
published papers on this subject (485 
studies), only six trials satisfied the strict 
inclusion criteria. In contrast to findings 
regarding patients with ventricular fibri-
llation, pulseless electrical activity or 
asystole, (4,10,23, 33-34) the results of 
clinical trials did not support the addi-
tion of vasopressin to epinephrine in 
cardiac arrest resuscitation, except in 
a subgroup looking at survival rate at 
24h. For in- hospital patients, the vaso-
pressin and epinephrine group failed 
to show any improvement compared 
with epinephrine for either 1 h survival 
or survival to hospital discharge. The 
combination of epinephrine and vaso-
Study or Subgroup





Heterogeneity: Chi² = 4.75, df = 2 (P = 0.09); I² = 58%































vaso and epi epi Peto Odds Ratio Peto Odds Ratio
Peto, Fixed, 95% CI
0.01 0.1 1 10 100
Favours epi only Favours vaso and epi
Figure 3.1. Return of spontaneous circulation following asystole.
Study or Subgroup





Heterogeneity: Chi² = 0.53, df = 2 (P = 0.77); I² = 0%































vaso and epi epi Peto Odds Ratio Peto Odds Ratio
Peto, Fixed, 95% CI
0.01 0.1 1 10 100
Favours epi only Favours vaso and epi
Figure 3.2. Return of spontaneous circulation following pulseless electrical 
activity.
Study or Subgroup
C.W. Callaway  2006






Heterogeneity: Chi² = 7.83, df = 4 (P = 0.10); I² = 49%











































vaso and epi epi Peto Odds Ratio Peto Odds Ratio
Peto, Fixed, 95% CI
0.01 0.1 1 10 100
Favours epi only Favours vaso and epi
Figure3.3. Return of spontaneous circulation following ventricular fibrillati-
on.









Figure 4. Funnel plot of all studies included in the meta-analysis.
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pressin was not shown to be better than 
epinephrine alone. Although vasopre-
ssin is banked in a Class IIb recommen-
dation in cardiac arrest that requires 
fair-to-good evidence with a majority 
of experts considering it an 'optional or 
alternative intervention', there is insuffi-
cient evidence to advocate the use of 
vasopressin plus epinephrine in CPR 
temporally.
This meta-analysis has some limitations. 
Firstly, we included three trials in the 
analysis that had recruited a small pro-
portion of patients (about 7%) who had 
experienced CPR. Exclusion of these 
trials did not affect the outcome of our 
analysis apparently. Secondly, the dose 
and the sequence of the two drugs diffe-
red between included trials. Thirdly, the 
included trials represented participants 
with a clinically heterogeneous level of 
risk (although statistical heterogeneity 
was low), which was directly related to 
the method of selection of the compa-
rison group in each study. As has been 
reported, the funnel plots showed a 
relatively symmetric distribution, but the 
point cloud did not have a distinctive 
funnel form. This was probably due to 
the relatively high heterogeneity and 
to the small number of primary studies 
included in the meta-analysis. Therefore 
a publication bias may have also occu-
rred. The majority of the included stu-
dies were performed at single sites, so 
therefore same staff could have treated 
both cases and controls with a possible 
contamination bias.
Conclusion
We failed to detect a trend favoring 
the combination of vasopressin and 
epinephrine, except for the survival rate 
at 24h. However, only 122 patients in 
two studies were involved in this com-
parison. We have no idea whether a 
proposal of the use of vasopressin and 
epinephrine should be recommended, 
unless further large randomized con-
trolled trials show more evidence of 
improved outcome. There is a need for 
randomized controlled trials (RCTs) to 
evaluate the addition of vasopressin to 
epinephrine in cardiac arrest. Howe-
ver, there is no adequate evidence to 
advocate the use of epinephrine plus 
vasopressin for cardiac arrest at this 
point in time.
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